When Pfizer (NYSE: PFE )
last reported earnings I was pretty ambivalent about the stock, and
since that late January piece the shares have lagged both the broader
market and pharma industry peers like Merck, Lilly, and Novartis.
It's not as though the company has been sitting still either, what with
positive clinical updates on its Prevnar vaccine and palbociclib
oncology drug. Dwarfing all of that is the potential megadeal for
British pharma company AstraZeneca (NYSE: AZN )
. Pfizer needs to guard against overpaying in this potential deal, but
these shares are getting closer to an interesting entry point for
long-term investors.
Read the full article here:
After Missing Earnings, Is Pfizer a Good Value?
No comments:
Post a Comment